$CLBS News

Last published 4y ago

4y agoCLBSCaladrius Biosciences and Cend Therapeutics Announce Closing of Merger and the Emergence of Lisata TherapeuticsGlobeNewswireCompany to commence trading on The Nasdaq Capital Market under Ticker Symbol "LSTA" Lisata has approximately $76 million in cash and investments following transaction close Lisata strengthens Board of Directors and Executive Leadership Team, a
4y agoCLBSCaladrius Biosciences Announces Approval of Merger and Name Change to Lisata TherapeuticsGlobeNewswireBASKING RIDGE, N.J., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) ("Caladrius" or the "Company"), announced today that, based upon the final vote count certified by the independent inspector of elections for the annual m
4y agoCLBSCaladrius Biosciences Announces Participation in Upcoming Investor Conferences in September 2022GlobeNewswireBASKING RIDGE, N.J., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) ("Caladrius" or the "Company"), a clinical-stage biopharmaceutical company developing innovative therapies designed to treat or reverse disease, today ann
4y agoCLBSCaladrius Biosciences' Prospective Merger Partner, Cend Therapeutics, Announces Collaboration Agreement with Roche to Evaluate CEND-1 in Combination with Immunotherapy to Treat Pancreatic CancerGlobeNewswireStudy to be part of Roche's Morpheus Platform designed to enable more rapid and efficient development of novel cancer immunotherapy combinations Agreement accelerated by Caladrius' initial investment in Cend BASKING RIDGE, N.J. and SAN
4y agoCLBSCaladrius Biosciences Reports Second Quarter 2022 Financial Results and Provides Business UpdateGlobeNewswireMerger with Cend Therapeutics remains on track to close in the third quarter of 2022, subject to stockholder approval, resulting in the formation of Lisata Therapeutics Conference call begins today at 4:30 p.m. Eastern time BASKING RIDGE, N.J., Aug
4y agoCLBSCaladrius Biosciences Completes Enrollment in Phase 1b Study of CLBS201 for the Treatment of Diabetic Kidney DiseaseGlobeNewswireBASKING RIDGE, N.J., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) ("Caladrius" or the "Company"), a clinical-stage biopharmaceutical company developing innovative therapies designed to treat or reverse disease, announced
4y agoCLBSCaladrius Biosciences to Host Second Quarter 2022 Financial Results Conference Call on Thursday, August 4, 2022, at 4:30 p.m. Eastern TimeGlobeNewswireBASKING RIDGE, N.J., July 28, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) ("Caladrius" or the "Company"), a clinical-stage biopharmaceutical company developing innovative therapies designed to treat or reverse disease, today anno
4y agoCLBSCaladrius Biosciences and Cend Therapeutics Announce Publication of Pancreatic Cancer Trial Data in The Lancet Gastroenterology and HepatologyGlobeNewswireBASKING RIDGE, N.J. and SAN DIEGO, July 06, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) ("Caladrius" or the "Company"), a clinical-stage biopharmaceutical company developing innovative therapies designed to treat or reverse disea
4y agoCLBSCend Therapeutics Announces First Patient Treated in Phase 2b Trial of CEND-1 led by Australasian Gastro-Intestinal Trials GroupGlobeNewswireSAN DIEGO, June 09, 2022 (GLOBE NEWSWIRE) -- Cend Therapeutics, Inc. ("Cend") today announced that the first patient has been treated in the Phase 2b study of CEND-1, Cend's lead investigational drug, in patients with first-line metastatic pancreatic d
4y agoCLBSCaladrius Biosciences Announces Merger Partner, Cend Therapeutics, has Treated First Patient in Phase 2b Trial of CEND-1 in Collaboration with Australasian Gastro-Intestinal Cancer Trials GroupGlobeNewswireBASKING RIDGE, N.J., June 09, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) ("Caladrius" or the "Company"), a clinical-stage biopharmaceutical company dedicated to the development of innovative therapies designed to treat or revers
4y agoCLBSCaladrius Biosciences to Present at the BIO International Convention 2022GlobeNewswireBASKING RIDGE, N.J., June 08, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) ("Caladrius" or the "Company"), a clinical-stage biopharmaceutical company dedicated to the development of innovative therapies designed to treat or rever
4y agoCLBSCaladrius Biosciences and Cend Therapeutics Announce Poster Presentation at the 2022 American Society of Clinical Oncology Annual MeetingGlobeNewswireBASKING RIDGE, N.J. and SAN DIEGO, May 26, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) ("Caladrius" or the "Company"), a clinical-stage biopharmaceutical company dedicated to the development of innovative therapies designed to tr
4y agoCLBSCaladrius Biosciences Provides Update on Phase 2b FREEDOM Trial of XOWNA® in Coronary Microvascular DysfunctionGlobeNewswireInterim analysis to be conducted following enrollment suspension in the double-blind, randomized, placebo-controlled clinical trial Next development steps for XOWNA® to be announced by year-end 2022 following regulatory and business review Caladr
4y agoCLBSCaladrius Biosciences Announces IDMC Recommendation to Advance CLBS201 Trial for the Treatment of Diabetic Kidney DiseaseGlobeNewswireIndependent Data Monitoring Committee advises continuation of trial without modification No safety or tolerability concerns observed in the first two patients dosed Top-line data from all subjects expected by the first quarter of 2023 BASKING RI
4y agoCLBSCaladrius Biosciences to Present at the H.C. Wainwright Global Investment ConferenceGlobeNewswireBASKING RIDGE, N.J., May 18, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) ("Caladrius" or the "Company"), a clinical-stage biopharmaceutical company dedicated to the development of innovative therapies designed to treat or revers
4y agoCLBSCaladrius Biosciences Reports First Quarter 2022 Financial Results and Provides Business UpdateGlobeNewswireSigns definitive merger agreement with Cend Therapeutics along with immediate investment and collaboration agreements Maintains strong financial position while advancing and expanding development portfolio Conference call begins today at 4:30 p
4y agoCLBSCaladrius Biosciences to Host First Quarter 2022 Financial Results Conference Call on Thursday, May 5, 2022, at 4:30 p.m. Eastern TimeGlobeNewswireBASKING RIDGE, N.J., April 28, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) ("Caladrius" or the "Company"), a clinical-stage biopharmaceutical company dedicated to the development of innovative therapies designed to treat or reve
4y agoCLBS CYN EVOK LCID+1Thinking about buying stock in Vivakor, Cyngn, Evoke Pharma, Lucid Group, or Caladrius Biosciences?PR NewswireNEW YORK, April 27, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for VIVK, CYN, EVOK, LCID, and CLBS.
4y agoCLBSCaladrius Biosciences and Cend Therapeutics Announce Definitive Merger AgreementGlobeNewswireCombined company to be renamed Lisata Therapeutics upon transaction closing Combination will create a financially sound Nasdaq-listed company with a diverse product development pipeline, strong existing partnerships and potential for future attractive
4y agoCLBSCaladrius Biosciences Treats First Patient in the Phase 1b Trial of CLBS201 for the Treatment of Diabetic Kidney DiseaseGlobeNewswireBASKING RIDGE, N.J., April 12, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) ("Caladrius" or the "Company"), a clinical-stage biopharmaceutical company dedicated to the development of innovative therapies designed to treat or reve
4y agoCLBSCaladrius Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business UpdateGlobeNewswireBASKING RIDGE, N.J., March 22, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) ("Caladrius" or the "Company"), a clinical-stage biopharmaceutical company dedicated to the development of innovative therapies designed to treat or rever
4y agoCLBSCaladrius Biosciences to Host Fourth Quarter and Full Year 2021 Financial Results Conference Call on Tuesday, March 22, 2022, at 4:30 p.m. Eastern TimeGlobeNewswireBASKING RIDGE, N.J., March 15, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) ("Caladrius" or the "Company"), a clinical-stage biopharmaceutical company dedicated to the development of innovative therapies designed to treat or rever
4y agoCLBSCaladrius Biosciences Receives $2.3 Million of Non-Dilutive Capital Through New Jersey Technology Business Tax Certificate Transfer ProgramGlobeNewswireBASKING RIDGE, N.J., March 01, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) ("Caladrius" or the "Company"), a clinical-stage biopharmaceutical company dedicated to the development of innovative therapies designed to treat or reve
4y agoCLBS LGVNLongeveron Adds Seasoned Biotech Executive Todd Girolamo to Its Board of DirectorsGlobeNewswireMIAMI, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic, aging-related and life-threatening conditions, announced today the ap
4y agoCLBSCaladrius Biosciences to Present at the BIO CEO & Investor ConferenceGlobeNewswireBASKING RIDGE, N.J., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) ("Caladrius" or the "Company"), a clinical-stage biopharmaceutical company dedicated to the development of innovative therapies designed to treat or rever
4y agoCLBS CLF CSLT DTST+1Thinking about buying stock in Lixte Biotechnology, Data Storage, Castlight Health, Cleveland-Cliffs, or Caladrius Biosciences?PR NewswireNEW YORK, Jan. 5, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for LIXT, DTST, CSLT, CLF, and CLBS. To
4y agoCLBSCaladrius Biosciences Announces Participation in Upcoming Conferences in January 2022GlobeNewswireBASKING RIDGE, N.J., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) ("Caladrius" or the "Company"), a clinical-stage biopharmaceutical company dedicated to the development of innovative therapies designed to treat or rever
5y agoCLBSCaladrius Biosciences Provides Corporate Update and Reports 2021 Third Quarter Financial ResultsGlobeNewswireCompany Reports Strong Cash Position as it Prepares to Initiate a CD34+ Cell Therapy Study in Diabetic Kidney Disease Conference call begins today at 4:30 p.m. Eastern time BASKING RIDGE, N.J., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Caladrius Bios
5y agoCLBSCaladrius Biosciences to Host Third Quarter 2021 Financial Results Conference Call on Thursday, November 4th at 4:30 p.m. Eastern TimeGlobeNewswireBASKING RIDGE, N.J., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) ("Caladrius" or the "Company"), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease,
5y agoCLBSCaladrius Biosciences Announces Participation in Upcoming Conferences in October 2021GlobeNewswireBASKING RIDGE, N.J., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) ("Caladrius" or the "Company"), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease,
5y agoCLBSCaladrius Biosciences to Present at the H.C. Wainwright 23rd Annual Global Investment ConferenceGlobeNewswireBASKING RIDGE, N.J., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) ("Caladrius" or the "Company"), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease,
5y agoCLBSCaladrius Biosciences Announces Appointment of Kristen K. Buck, M.D., as Chief Medical OfficerGlobeNewswireBASKING RIDGE, N.J., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) ("Caladrius" or the "Company"), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease,
5y agoCLBSCaladrius Biosciences Reports Second Quarter 2021 Financial Results and Provides Business UpdateGlobeNewswireBASKING RIDGE, N.J., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) ("Caladrius" or the "Company"), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease,
5y agoCLBSA Phase 1/2 Study Evaluating the Safety and Efficacy of CLBS201 in Patients With Chronic Kidney Disease and Type 2 Diabetes Mellitus - NCT04990427ClinicalTrials.govSerious Adverse Events, Estimated Glomerular Filtration Rate (eGFR), Serum Creatinine (SCr)
5y agoCLBSCaladrius Biosciences to Host Second Quarter 2021 Financial Results Conference Call on Thursday, August 5, 2021 at 4:30 p.m. Eastern TimeGlobeNewswireBASKING RIDGE, N.J., July 29, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) ("Caladrius" or the "Company"), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease,
5y agoCLBSCaladrius Biosciences to Present at Zooming with LDGlobeNewswireBASKING RIDGE, N.J., July 22, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) ("Caladrius" or the "Company"), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease,
5y agoCLBSCaladrius Biosciences to Assess its CLBS201 CD34+ Cell Therapy in Diabetic Kidney DiseaseGlobeNewswireBASKING RIDGE, N.J., June 22, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) ("Caladrius" or the "Company"), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease,
5y agoCLBSCaladrius Biosciences to Present at Noble Capital Markets Virtual Investor Forum during the 16th Annual World Stem Cell SummitGlobeNewswireBASKING RIDGE, N.J., June 17, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) ("Caladrius" or the "Company"), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease,
5y agoCLBSCaladrius Biosciences Reports First Quarter 2021 Financial Results and Provides Business UpdateGlobeNewswireBASKING RIDGE, N.J. , May 06, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) ("Caladrius" or the "Company"), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease,
5y agoCLBSCaladrius Biosciences, Inc. to Host Earnings CallACCESS NewswireNEW YORK, NY / ACCESSWIRE / May 6, 2021 / Caladrius Biosciences, Inc. (NASDAQ:CLBS) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on May 6, 2021 at 4:30 PM Eastern Time. To listen to the event live or acc
5y agoCLBSCaladrius Biosciences Announces Participation in Upcoming Virtual Conferences in May 2021GlobeNewswireBASKING RIDGE, N.J., May 04, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) ("Caladrius" or the "Company"), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease,
5y agoCLBSCaladrius Biosciences to Host First Quarter 2021 Financial Results Conference Call on Thursday, May 6, 2021 at 4:30 p.m. Eastern TimeGlobeNewswireBASKING RIDGE, N.J., April 29, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) ("Caladrius" or the "Company"), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease,
5y agoCLBSCaladrius Biosciences Announces Orphan Drug Designation for CLBS12 for the Treatment of Buerger’s DiseaseGlobeNewswireBASKING RIDGE, N.J., March 08, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the...
5y agoCLBSCaladrius Biosciences to Present at the H.C. Wainwright Global Life Sciences Virtual ConferenceGlobeNewswireBASKING RIDGE, N.J., March 03, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the...
5y agoCLBSCaladrius Biosciences Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business UpdateGlobeNewswireCompany demonstrates resilience despite COVID-19 challenges: Financial situation secure and development programs progressing Conference call begins today at 4:30 p.m. (ET) BASKING RIDGE, N.J., Feb. ...
5y agoCLBSCaladrius Biosciences to Host Fourth Quarter and Full Year 2020 Financial Results Conference Call on Thursday, February 25, 2021 at 4:30 p.m. Eastern TimeGlobeNewswireBASKING RIDGE, N.J., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the...
5y agoCLBSCaladrius Biosciences, Inc. Closes $65 Million Registered Direct Offerings Priced At-The-Market under Nasdaq RulesGlobeNewswireBASKING RIDGE, N.J., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the...
5y agoCLBSCaladrius Biosciences, Inc. Announces $65 Million Registered Direct Offerings Priced At-The-Market under Nasdaq RulesGlobeNewswireBASKING RIDGE, N.J., Feb. 12, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the...
5y agoCLBSCaladrius Biosciences Closes $25.0 Million Private PlacementGlobeNewswireBASKING RIDGE, N.J., Jan. 25, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the...
5y agoCLBSCaladrius Biosciences Announces Participation in Upcoming Virtual Conferences in February 2021GlobeNewswireBASKING RIDGE, N.J., Jan. 25, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the...